Matthew Pakizegee, PharmD, MS

Oncolytic Biosimilars: An Opportunity to Reduce Oncology Treatment Costs

Clinical Pathways GPS

04/21/2020

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Inclusion of oncology biosimilars in clinical pathways is one approach to reducing costs in this therapeutic area without compromising outcomes for cancer patients. There are currently eight Food and Drug...

...

04/21/2020

Journal of Clinical Pathways

Clinical Pathways GPS

Speaker Pelosi’s Plan to Lower Drug Costs

11/18/2019

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Matthew Pakizegee , PharmD, MS;

As total cost of care increasingly becomes a major issue in the United States, both market solutions like clinical pathways and government solutions such as drug pricing regulations are being proposed. Each solution...

As...

11/18/2019

Journal of Clinical Pathways

Clinical Pathways GPS

Ramifications of “Medicare for All” and Implications for Clinical Pathways

08/19/2019

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Matthew Pakizegee , PharmD, MS;

As the Medicare for All (M4A) debate continues into 2020, clinical pathway organizations, payers, health systems, providers, and patients will all play a role in shaping future policies around patient access and...

As the...

08/19/2019

Journal of Clinical Pathways

Clinical Pathways GPS

CMS Policies Concerning CAR T-Cell Therapy

05/15/2019

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Matthew Pakizegee , PharmD, MS;

Chimeric antigen receptor (CAR) T-cell therapy is a new form of cancer therapy that uses a patient’s own immune system to fight the disease. This type of cell therapy uses an individualized process to develop a...

...

05/15/2019

Journal of Clinical Pathways

Clinical Pathways GPS

Centers of Excellence: Criteria and Comprehensive Clinical Pathways

03/13/2019

Matthew Pakizegee , PharmD, MS;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

The Center of Excellence (CoE) model of care is an excellent approach to the growing need for disease-based medical management of chronic-type conditions with its multidisciplinary team approach and dedication to...

The...

03/13/2019

Journal of Clinical Pathways

Clinical Pathways GPS

Pathways for Paying for Rare Disease Treatments

02/22/2019

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Matthew Pakizegee , PharmD, MS;

Determining how to pay for the treatment of uncommon yet serious diseases is an important consideration in terms of sustainability and patient access. Novel and expensive therapies will create financial pressure for...

...

02/22/2019

Journal of Clinical Pathways

Clinical Pathways GPS

Value-Based Clinical Pathways in the World of Reference-Priced Medicare Part B Drugs

12/13/2018

Matthew Pakizegee , PharmD, MS;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

The Centers for Medicare & Medicaid Services (CMS) released an advanced notice of proposed rulemaking on October 25, 2018, seeking to test  whether using a combination of 3 approaches—an international drug...

The...

12/13/2018

Journal of Clinical Pathways